SGBI - Sangui Biotech International, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Sangui Biotech International, Inc.

Alfred Herrhausen Street 44
Witten 58455
Germany
49 2302 915 200
http://www.sanguibiotech.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas StriepeCEO, Pres, CFO & Exec. Director19.25kN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through Internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is based in Witten, Germany.

Corporate Governance

Sangui Biotech International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.